Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control

Tuberculosis

Volumn 90, Issue 3, 2010, Pages 182-187

  Fears, Robin ^a   Kaufmann, Stefan ^b   ter Meulen, Volker ^c   Zumla, Alimuddin ^d  

^a Royal Society   (United Kingdom)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c German Academy of Sciences   (Germany)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Control; Drug resistant TB; EASAC; Europe; Funding; TB

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; DATA BASE; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; EUROPEAN UNION; EVIDENCE BASED MEDICINE; GENOTYPE; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLIC HEALTH SERVICE; REVIEW; SOCIOECONOMICS; SPUTUM SMEAR; SUSTAINABLE DEVELOPMENT; TUBERCULOSIS; TUBERCULOSIS CONTROL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; EUROPEAN UNION; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PUBLIC HEALTH; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77952550817     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.03.008     Document Type: Review

References (36)

1. WHO Report. Global tuberculosis control 2009 - epidemiology, strategy and financing (2009). 9789241563802. WHO/HTM/TB/2009.411
2. Wright A., Zignol M., Van Deun A., Falzon D., Gerdes S.R., Feldman K., et al. For the global project on anti-tuberculosis drug resistance surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet (2009) [Apr 15 Epub ahead of print]
3. Report 2008: 8th National TB Programme Managers Meeting and the 13th Wolfheze Workshop. Wolfheze 2008: tuberculosis management, surveillance and evaluation in Europe with high rates or threat of mtulidrug resistant tuberculosis, The Hague, The Netherlands 1-2 June 2008. http://www.euro.who.int/document/E92047.pdf
4. Broekmans J.F., Migliori G.B., Rieder H.L., Lees J., Ruutu P., Loddenkemper R., et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO) International Union against tuberculosis and lung disease, and Royal Netherlands Tuberculosis Association working Group. Eur Resp J 4 (2002) 590-592
5. EASAC policy report 10. Drug-resistant tuberculosis: challenges, consequences and strategies for control. Pages 1-40 (2009). 978-0-85403-746-9. www.easac.eu
6. Migliori G.B., Besozzi G., Girardi E., Kliiman K., Lange C., Toungoussova O.S., et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 5 (2008) 1413-1415
7. Sotgiu G., Ferrara G., Matteelli A., Richardson M.D., Centis R., Ruesch-Gerdes S., et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Resp J 4 (2009) 871-881
8. Migliori G.B., Loddenkemper R., Blasi F., and Raviglione M.C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. Eur Respir J 29 3 (2007) 423-427
9. Schmidt C. An evolving threat. Nat Med 14 (2008) 904-907
10. Falzon D., Kudjawu Y., Desenclos J.-C., de la Hoz K.F., Dadu A., and Zaleskis R. Stopping TB in Europe: some progress but still not there. Eurosurveillance 13 (2008) 1-5
11. Davies P.D.O., and Cullen D. Service for drug resistant tuberculosis exists in the UK. BMJ 336 (2008) 1324
12. Kaufmann S.H.E., and Parida S.K. Changing funding patterns in tuberculosis. Nat Med 13 (2007) 299-303
13. Zumla A. Tuberculosis - the tide can be turned the battle can be won. J R Soc Med 101 (2008) 100-101
14. International Conference 13th/14th November 2008 held by the EC-research-health on 'challenges for the future: research on HIV/AIDS, malaria and tuberculosis'. website:. http://ec.europa.eu/research/conferences/2008/poverty-related-diseases/programme_en.html
15. Anon. Research and discovery. Nat Med 14 (2008) 1129
16. Georghiou L. Europe's research system must change. Nature 452 (2008) 935-936
17. Keshavjee S., and Seung K. Stemming the tide of multidrug-resistant tuberculosis: major barriers to addressing the growing epidemic (2008), Institute of Medicine Report. www.iom.edu/Object.File/Master/60/204/IOM_MDRTB_whitepaper_2008_11_05_FINAL.pdf
18. ECDC. Framework action plan to fight tuberculosis in the European Union. ECDC Report (2008). http://www.ecdceuropa.eu
19. Drobniewski F.A., Nikolayevskyy V., Hoffner S., Pogoryelova D., Manissero D., and Ozin A.J. The added value of a European Union tuberculosis reference laboratory network - analysis of the national reference laboratory activities. Eurosurveillance 13 (2008) 1-7
20. Gessler D., Dye C., Farmer P., Murray M., Navin T., Reves R., et al. A national tuberculosis archive. Science 311 (2006) 1245-1246
21. Kaufmann S.H.E. Tuberculosis: deadly combination. Nature 453 (2008) 295
22. Legrand J., Sanchez A., Le Pont F., Camacho L., and Larouze B. Modeling the impact of tuberculosis control strategies in highly endemic overcrowded prisons. PLoS ONE 3 (2008) e2100 10.1371/journal.pone.0002100
23. EASAC. Impact of migration on infectious diseases in Europe. Royal Soc (2007) 1-8. www.easac.eu
24. Hopewell P.C., Fair P.L., and Pai M. International standards for TB care. [Chapter 63]. In: Schaaf S., and Zumla A. (Eds). Tuberculosis: a comprehensive clinical reference (2009), Saunders Elsevier, London, UK. 9781416039884 649-659
25. Dheda K., Onyebujoh P., Vahedi M., and Zumla A. Priorities in TB research. In: Schaaf S., and Zumla A. (Eds). Tuberculosis: a comprehensive clinical reference (2009), Saunders Elsevier, London, UK. 9781416039884 746-758 [Chapter 73]
26. Moszynski P. European commission is not paying its share towards TB research, charity says. BMJ 337 (2008) a2550 10.1136/bmj.a2550
27. Feuer C. Available at:. In: Harrington M., Huff B., and Syed J. (Eds). Tuberculosis research and development: a critical analysis of funding trends 2005-2006. Treatment Action Group (2007). www.treatmentactiongroup.org
28. Cough up for TB! (2008), 3 Medecins Sans Frontiere. http://www.msfaccess.org
29. Anon. New year resolutions. Nat Med 15 (2009) 1
30. Nantulya V.M. Getting diagnostics into countries. Available at:. In: Matlin S., de Francisco A., Sundaram L., Faich H.-S., and Gehner M. (Eds). Global forum for health research: health partnerships review (2008) 68-72. www.globalforumhealth.org
31. Fauci A.S., and the NIAID Tuberculosis Working Group. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Disease research agenda and recommendations for priority research. J Infect Dis 197 (2008) 1-6
32. Syhre M., and Chambers S.T. The scent of Mycobacterium tuberculosis. Tuberculosis 88 (2008) 317-323
33. Hoft D.F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372 (2008) 164-175
34. EASAC. Vaccines: innovation and human health. Royal Soc (2006)
35. Glickman S.W., Rasiel E.B., Dukes Hamilton C., Kubataev A., and Schulman K.A. A portfolio model of drug development for tuberculosis. Science 311 (2006) 1246-1247
36. EASAC. Tackling antibacterial resistance in Europe. Royal Soc (2007) 1-34 ISBN: 978-0-85403-638-7